UY31896A - Derivados de 5-(4-metanosulfonil-fenil)-tiazol para el tratamiento de enfermedades inflamatorias agudas y crónicas - Google Patents
Derivados de 5-(4-metanosulfonil-fenil)-tiazol para el tratamiento de enfermedades inflamatorias agudas y crónicasInfo
- Publication number
- UY31896A UY31896A UY0001031896A UY31896A UY31896A UY 31896 A UY31896 A UY 31896A UY 0001031896 A UY0001031896 A UY 0001031896A UY 31896 A UY31896 A UY 31896A UY 31896 A UY31896 A UY 31896A
- Authority
- UY
- Uruguay
- Prior art keywords
- acute
- treatment
- chronic inflammatory
- methanosulphonyl
- tiazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08380177A EP2135864A1 (en) | 2008-06-16 | 2008-06-16 | 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases |
US12/139,661 US7781594B2 (en) | 2008-06-16 | 2008-06-16 | 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31896A true UY31896A (es) | 2010-01-29 |
Family
ID=43414178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001031896A UY31896A (es) | 2008-06-16 | 2009-06-12 | Derivados de 5-(4-metanosulfonil-fenil)-tiazol para el tratamiento de enfermedades inflamatorias agudas y crónicas |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP2313382A1 (zh) |
JP (1) | JP2011524352A (zh) |
KR (1) | KR20110022679A (zh) |
CN (1) | CN102083806A (zh) |
AR (1) | AR072113A1 (zh) |
AU (1) | AU2009259451B2 (zh) |
BR (1) | BRPI0915325A2 (zh) |
CA (1) | CA2728139A1 (zh) |
CO (1) | CO6331429A2 (zh) |
IL (1) | IL209801A0 (zh) |
MA (1) | MA32473B1 (zh) |
MX (1) | MX2010013978A (zh) |
NZ (1) | NZ589894A (zh) |
RU (1) | RU2495031C2 (zh) |
SA (1) | SA109300384B1 (zh) |
TW (1) | TWI403506B (zh) |
UY (1) | UY31896A (zh) |
WO (1) | WO2009153226A1 (zh) |
ZA (1) | ZA201008877B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2961695B1 (fr) * | 2010-06-29 | 2012-07-06 | Galderma Res & Dev | Utilisation de composes dans le traitement ou la prevention de troubles cutanes |
RU2502513C2 (ru) * | 2012-01-11 | 2013-12-27 | Государственное бюджетное учреждение здравоохранения Свердловской области "Свердловский областной клинический психоневрологический госпиталь для ветеранов войн" (ГБУЗ СО "СОКП Госпиталь для ветеранов войн") | Способ лечения больных с полиорганной патологией озонотерапией |
AU2018371177B2 (en) * | 2017-11-23 | 2023-10-19 | Immunic Ag | Dosage regimen of vidofludimus for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases |
KR102076936B1 (ko) * | 2019-08-12 | 2020-02-13 | 연세대학교 산학협력단 | 티아졸 또는 이의 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염 예방 또는 치료용 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990009381A1 (en) * | 1989-02-08 | 1990-08-23 | Abbott Laboratories | 4-hydroxythiazoles as 5-lipoxygenase inhibitors |
JPH10504542A (ja) * | 1994-07-27 | 1998-05-06 | ジー.ディー.サール アンド カンパニー | 炎症処置用の置換チアゾール化合物 |
CA2224517A1 (en) * | 1995-06-12 | 1996-12-27 | G.D. Searle & Co. | Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
WO2001027094A1 (fr) * | 1999-10-12 | 2001-04-19 | Japan Tobacco Inc. | Remede anti-hypertriglyceridemie et anti-obesite |
AU2002331227B2 (en) * | 2001-08-13 | 2008-01-24 | Janssen Pharmaceutica N.V. | 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity |
US20050026902A1 (en) * | 2003-01-31 | 2005-02-03 | Timothy Maziasz | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents |
-
2009
- 2009-06-06 TW TW098118927A patent/TWI403506B/zh not_active IP Right Cessation
- 2009-06-12 UY UY0001031896A patent/UY31896A/es not_active Application Discontinuation
- 2009-06-12 AR ARP090102121A patent/AR072113A1/es unknown
- 2009-06-15 RU RU2011101439/04A patent/RU2495031C2/ru not_active IP Right Cessation
- 2009-06-15 CN CN2009801226820A patent/CN102083806A/zh active Pending
- 2009-06-15 WO PCT/EP2009/057324 patent/WO2009153226A1/en active Application Filing
- 2009-06-15 CA CA2728139A patent/CA2728139A1/en not_active Abandoned
- 2009-06-15 KR KR1020117001228A patent/KR20110022679A/ko not_active Application Discontinuation
- 2009-06-15 JP JP2011513001A patent/JP2011524352A/ja active Pending
- 2009-06-15 BR BRPI0915325A patent/BRPI0915325A2/pt not_active IP Right Cessation
- 2009-06-15 AU AU2009259451A patent/AU2009259451B2/en not_active Ceased
- 2009-06-15 MX MX2010013978A patent/MX2010013978A/es active IP Right Grant
- 2009-06-15 SA SA109300384A patent/SA109300384B1/ar unknown
- 2009-06-15 NZ NZ589894A patent/NZ589894A/en not_active IP Right Cessation
- 2009-06-15 EP EP09765806A patent/EP2313382A1/en not_active Withdrawn
-
2010
- 2010-12-06 IL IL209801A patent/IL209801A0/en unknown
- 2010-12-09 ZA ZA2010/08877A patent/ZA201008877B/en unknown
-
2011
- 2011-01-13 MA MA33516A patent/MA32473B1/fr unknown
- 2011-01-14 CO CO11003796A patent/CO6331429A2/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
TW201010988A (en) | 2010-03-16 |
CO6331429A2 (es) | 2011-10-20 |
NZ589894A (en) | 2011-08-26 |
MA32473B1 (fr) | 2011-07-03 |
AU2009259451B2 (en) | 2013-03-14 |
AU2009259451A1 (en) | 2009-12-23 |
JP2011524352A (ja) | 2011-09-01 |
WO2009153226A1 (en) | 2009-12-23 |
ZA201008877B (en) | 2012-02-29 |
EP2313382A1 (en) | 2011-04-27 |
RU2495031C2 (ru) | 2013-10-10 |
IL209801A0 (en) | 2011-02-28 |
TWI403506B (zh) | 2013-08-01 |
AR072113A1 (es) | 2010-08-04 |
CA2728139A1 (en) | 2009-12-23 |
CN102083806A (zh) | 2011-06-01 |
KR20110022679A (ko) | 2011-03-07 |
MX2010013978A (es) | 2011-03-29 |
RU2011101439A (ru) | 2012-07-27 |
SA109300384B1 (ar) | 2013-04-20 |
BRPI0915325A2 (pt) | 2015-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
CO6382125A2 (es) | Inhibidores de proteína quinasa | |
ECSP088902A (es) | Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios | |
MX2014000341A (es) | Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades. | |
MX2010007375A (es) | Nuevos derivados de lupano. | |
JP2013542247A5 (zh) | ||
DOP2006000170A (es) | Nuevos derivados de espirocromanona | |
AR062394A1 (es) | Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis | |
MX2010007374A (es) | Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos. | |
UA109421C2 (uk) | Фармацевтична композиція, яка містить ліганди сигма-рецептора | |
GT201200164A (es) | "nuevos compuestos de espiropiperidina" | |
CR11208A (es) | Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas | |
ECSP12011703A (es) | Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos | |
ECSP13012812A (es) | Formulaciones inmunosupresoras | |
EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты | |
PE20121523A1 (es) | Metodo de tratamiento | |
JP2009537554A5 (zh) | ||
WO2008098985A3 (en) | Pharmaceutical composition for the treatment of il-8 mediated diseases | |
AR062390A1 (es) | Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas | |
MX2021003739A (es) | Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos. | |
UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
UY31896A (es) | Derivados de 5-(4-metanosulfonil-fenil)-tiazol para el tratamiento de enfermedades inflamatorias agudas y crónicas | |
BR112013012665A2 (pt) | composto de fórmula (i), ou um sal, pró-droga ou solvato do mesmo e composição farmacêutica | |
JP2011012060A5 (zh) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20181031 |